95 related articles for article (PubMed ID: 10470182)
1. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time.
Heinze T; Jonas S; Kärsten A; Neuhaus P
Anticancer Res; 1999; 19(4A):2501-3. PubMed ID: 10470182
[TBL] [Abstract][Full Text] [Related]
2. p53 determination in gynecological carcinomas: immunohistochemistry compared to luminometric immunoassay (LIA).
Heinze T; Greiner-Mai E; Lichtenegger W
Anticancer Res; 1999; 19(4A):2505-8. PubMed ID: 10470183
[TBL] [Abstract][Full Text] [Related]
3. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.
Hsu HC; Tseng HJ; Lai PL; Lee PH; Peng SY
Cancer Res; 1993 Oct; 53(19):4691-4. PubMed ID: 8402647
[TBL] [Abstract][Full Text] [Related]
5. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma.
Ng KT; Qi X; Kong KL; Cheung BY; Lo CM; Poon RT; Fan ST; Man K
Eur J Cancer; 2011 Oct; 47(15):2299-305. PubMed ID: 21683576
[TBL] [Abstract][Full Text] [Related]
8. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
9. Thymidine phosphorylase activity in liver tissue and its correlation with multifocal occurrence of hepatocellular carcinomas.
Ikeguchi M; Sakatani T; Ueda T; Hirooka Y; Kaibara N
In Vivo; 2001; 15(4):265-70. PubMed ID: 11695216
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
11. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
12. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
13. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma.
Lee TK; Man K; Poon RT; Lo CM; Ng IO; Fan ST
Oncol Rep; 2004 Jul; 12(1):25-31. PubMed ID: 15201954
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
Nanashima A; Yano H; Yamaguchi H; Tanaka K; Shibasaki S; Sumida Y; Sawai T; Shindou H; Nakagoe T
J Gastroenterol; 2004; 39(2):148-54. PubMed ID: 15069621
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis.
Mise K; Tashiro S; Yogita S; Wada D; Harada M; Fukuda Y; Miyake H; Isikawa M; Izumi K; Sano N
Clin Cancer Res; 1998 Jun; 4(6):1475-82. PubMed ID: 9626465
[TBL] [Abstract][Full Text] [Related]
16. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
[TBL] [Abstract][Full Text] [Related]
17. C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms.
Vlasoff DM; Baschinsky DY; De Young BR; Morrison CD; Nuovo GJ; Frankel WL
Appl Immunohistochem Mol Morphol; 2002 Sep; 10(3):237-41. PubMed ID: 12373150
[TBL] [Abstract][Full Text] [Related]
18. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
19. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
